New Study Guardant360® liquid biopsy test – PIK3CA Mutations

Dr. Becky Nagy, Vice President of Medical Affairs at Guardant Health discusses the phase l/ll study led by Memorial Sloan Kettering Cancer Center and published in “Nature Cancer” that showed Guardant360® liquid biopsy test identifies predictors of response to PIK3CA inhibitors in women with HR+ Metastatic Breast Cancer. 

Dr. Rebecca “Becky” Nagy.  Experienced Vice President of Medical Affairs with a demonstrated history of working in the biotechnology industry. Skilled in Oncology, Molecular Oncology, Cancer Genomics, Human Genetics, and Molecular Genetics. Strong research professional with a Master’s Degree focused on Genetic Counseling/Counselor from University of Minnesota-Twin Cities.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.